Ro KhannaSell
IONS Common Stock · Transaction Mar 14, 2023 · Filed Apr 7, 2023 · Amount pending receipt enrichment
NASDAQ NMS - GLOBAL MARKET · IONS
+1.33% · +$0.7800 · Vol 3.2M
After hours · updated 18:27:53 ET
Ionis Pharmaceuticals Inc
Biotechnology
$59.41
Veridion Score
BETAHIGH CONF · 6/6 factorsTue Aug 18 · session closed · Markets closed · resumes Wed 9:30 ET · IONS
MethodologyIONS
Ionis Pharmaceuticals Inc
Tue Aug 18 · session closed · Markets closed · resumes Wed 9:30 ET
SELL BIAS
Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.
35/ 100
Veridion Score
SELL BIAS · HIGH confidence
Sovereign · $25/mo
See why this score moved.
- · Factor breakdown with raw signals
- · Day-over-day delta + driver
- · Factor coverage readout
- · Valuation · hype · market flow
- · Pro Chart event markers
- · Score history + alerts
Start Sovereign · $25/mo →
Cancel anytime · or Reserve · $79/mo
Confidence: HIGH · 6/6 factors with data · Tue Aug 18 · session closed · Markets closed · resumes Wed 9:30 ET
Veridion Score History · 90D
Loading score history
AI Analysis
SovereignWhy is IONS moving today?
Sovereign unlock connects news, insider activity, analyst moves, and live price action.
About Ionis Pharmaceuticals Inc
PHARMACEUTICAL PREPARATIONSListed since
1991
Employees
1K
Country
US
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis marked its first two independent launches in 2025 for Tryngolza (for FCS) and Dawnzera (for HAE).
Key statistics
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
Open
$58.41
Day high
$60.19
Day low
$58.02
Previous close
$58.63
52W high
$86.50
-31.32% from high
52W low
$41.82
39% of range
Market cap
$9.7B
EPS
$-1.3500
Beta
-0.18
Shares out
166.2M
Volume
3.2M
0.83× rel vol
Avg volume
3.9M
VWAP
$59.42
Price history computed in-house
1W
+7.20%
1M
+9.23%
3M
-20.85%
1Y
+36.79%
YTD
-24.90%
SMA 50 $64.86 · below
SMA 200 $74.20 · below
52W position 39%
IONS overview
Related filings and maps
Public disclosures
Congress activity in IONS
Official filing ↗
Daniel GoldmanSell
IONS · Transaction Mar 6, 2023 · Filed Apr 17, 2023 · $1,001 to $15,000
Ro KhannaExchange
IONS Common Stock · Transaction Jan 4, 2023 · Filed Jan 6, 2023 · Amount pending receipt enrichment
Donna ShalalaSell
IONS Common Stock · Transaction Jun 24, 2019 · Filed Apr 27, 2020 · Amount pending receipt enrichment
IONS Common Stock · Transaction May 8, 2019 · Filed Apr 27, 2020 · Amount pending receipt enrichment
Federal contracts
IONS contract awards, year to date.
Public federal awards linked to this ticker.
Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for IONS in this window.
Lobbying spend
IONS lobbying filings, year to date.
Registered lobbying filings matched to Ionis Pharmaceuticals Inc.
$530.0K
Refresh interval: 12hSource: LDA disclosure filings
Health IssuesHealth Issues
Medicare/Medicaid
Taxation/Internal Revenue CodeMedicare/Medicaid
Taxation/Internal Revenue Code
Health Issues
Filing
$150.0K
IONIS PHARMACEUTICALS INC.
IONIS PHARMACEUTICALS, INC.
Jul 17, 2026
Filing
$150.0K
IONIS PHARMACEUTICALS INC.
IONIS PHARMACEUTICALS, INC.
Apr 9, 2026
Filing
$140.0K
IONIS PHARMACEUTICALS INC.
IONIS PHARMACEUTICALS, INC.
Jan 18, 2026
Analyst ratings
Sovereign unlock shows live analyst consensus for IONS.
Options
Sovereign unlock shows live options positioning for IONS.